BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24366407)

  • 1. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.
    Fortunati N; Marano F; Bandino A; Frairia R; Catalano MG; Boccuzzi G
    Int J Oncol; 2014 Mar; 44(3):700-8. PubMed ID: 24366407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
    Chen S; Ye J; Kijima I; Evans D
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11032-7. PubMed ID: 20534486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERalpha signaling through slug regulates E-cadherin and EMT.
    Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
    Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modification restores functional PR expression in endometrial cancer cells.
    Yang S; Xiao X; Jia Y; Liu X; Zhang Y; Wang X; Winters CJ; Devor EJ; Meng X; Thiel KW; Leslie KK
    Curr Pharm Des; 2014; 20(11):1874-80. PubMed ID: 23888956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
    de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
    Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
    Law ME; Corsino PE; Jahn SC; Davis BJ; Chen S; Patel B; Pham K; Lu J; Sheppard B; Nørgaard P; Hong J; Higgins P; Kim JS; Luesch H; Law BK
    Oncogene; 2013 Mar; 32(10):1316-29. PubMed ID: 22543582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
    Shah P; Gau Y; Sabnis G
    Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
    Zhou Q; Atadja P; Davidson NE
    Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
    Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.
    Gahr S; Mayr C; Kiesslich T; Illig R; Neureiter D; Alinger B; Ganslmayer M; Wissniowski T; Fazio PD; Montalbano R; Ficker JH; Ocker M; Quint K
    Int J Oncol; 2015 Sep; 47(3):963-70. PubMed ID: 26202945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-elemene decreases cell invasion by upregulating E-cadherin expression in MCF-7 human breast cancer cells.
    Zhang X; Zhang Y; Li Y
    Oncol Rep; 2013 Aug; 30(2):745-50. PubMed ID: 23732279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
    Rahimian A; Barati G; Mehrandish R; Mellati AA
    Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat inhibits breast cancer progression via Vps34-mediated exosomal pathway.
    Wang X; Yin X
    Hum Cell; 2023 Jan; 36(1):366-376. PubMed ID: 36329365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.